SponsorSpring Bank Pharma
Site Staff Materials
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of orally bioavailable therapeutics based on its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins or enzymes implicated in various disease states.
The Company is developed its most advanced SMNH product candidate, SB 9200, for the treatment of hepatitis B. SB 9200 has been designed to selectively activate the host cellular proteins, RIG I and NOD 2, which have been implicated in the body's immune response to viral infections. This clinical study was designed to evaluate what role the investigational drug could play in antiviral therapy by modulating host immune response to fight viral infections such as HBV.